|
|
Article: /C O R R E C T I O N -- CeloNova BioSciences, Inc./.
- Article from:
- PR Newswire Europe
- Article date:
- October 31, 2009
CopyrightCOPYRIGHT 2009 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NEWNAN, Georgia, October 31 /PRNewswire/ --
In the news release, French Physicians to Conduct 2000-Patient Study of CATANIA(TM) Coronary Stent, issued Oct. 30, 2009, by CeloNova BioSciences, Inc., over PR Newswire, the second paragraph should read:
The study will evaluate the short-, mid- and long-term safety and efficacy of the CATANIA(TM) coronary stent for the treatment of up to three de novo native coronary artery lesions in a real world setting. "Professor Teiger and Doctor Barragan are independent and respected interventional cardiologists and we look forward to the results of their study," said Thomas A. Gordy, President and Chief Executive Officer ...
Related newspaper, magazine, and journal articles:
|
|
Article: CeloNova BioSciences Announces World's First Line ...
PR Newswire Europe;
September 9, 2007 ;
700+ words
... ... 9 /PRNewswire/ -- CeloNova BioSciences, Inc. ("CeloNova ... particles, Embozene(TM) Color-Advanced Microspheres ... in mind. Embozene(TM) Color-Advanced Microspheres ... procedure." Embozene(TM) Color-Advanced Microspheres ... physician preference. About CeloNova BioSciences, Inc. ...
|
|